BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first de. ...

Company Overview - Stoke Therapeutics is a biotechnology company focused on restoring protein expression through RNA medicine, with its lead investigational medicine, zorevunersen, aimed at treating Dravet syndrome, a severe neurodevelopmental disorder characterized by recurrent seizures and cognitive impairments [3][9] - The company was founded in 2015 and has advanced zorevunersen from early clinical testing to late-stage development, preparing for commercialization in the United States [4][9] New Headquarters - Stoke Therapeutics has secured a long-term lease for a new 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, Massachusetts, which is one of the largest leases in the Greater Boston life sciences sector over the past year [1][2] - The relocation is set to occur when the current lease in Bedford, Massachusetts ends in late 2026 [1] Growth and Research Expansion - The new headquarters will support Stoke's growth trajectory as it prepares to commercialize zorevunersen and expand research efforts for additional medicines targeting severe diseases [5] - The Waltham area is recognized as a resilient hub for life sciences, providing operational efficiency and access to top talent, which aligns with Stoke's strategic goals [5] Infrastructure and Sustainability - The new property is LEED Gold and WiredScore Platinum certified, emphasizing sustainability and connectivity, with modern infrastructure designed for lab-ready use [5] Market Context - Despite a moderation in the national life sciences market, the Greater Boston area, particularly Waltham and the Route 128 corridor, continues to demonstrate strength and resilience in supporting the biotech industry [5]

Market Overview - The RNA therapy market is projected to grow from USD 18.77 billion in 2025 to USD 19.70 billion in 2026, with a compound annual growth rate (CAGR) of 6.40%, reaching USD 28.99 billion by 2032, driven by clinical proof, supply chain improvements, and regional investments [1][6]. Therapeutic Applications - RNA-based therapeutics are applicable in various therapeutic areas, including cardiovascular diseases, genetic disorders, infectious diseases, metabolic and neurological diseases, oncology (hematological cancers and solid tumors), and rare conditions like Gaucher disease and sickle cell disease, broadening the market scope [4]. Delivery Platforms - Delivery platforms for RNA therapies include exosomes, lipid nanoparticles, polymer carriers, and viral vectors, which influence targeting ability, immune response, production scale, and clinical trial timelines, allowing developers to customize delivery methods [4]. End-User Groups - The end-user groups for RNA therapies consist of biotechnology companies, pharmaceutical manufacturers, hospitals, clinics, and research institutes, shaping commercialization strategies and market entry timings [4]. Geographic Regions - The RNA therapy market spans the Americas, Europe, the Middle East & Africa, and Asia-Pacific, each presenting unique regulatory challenges, adoption rates, and infrastructure capabilities, necessitating navigation of regional nuances [4]. Strategic Considerations - Successful RNA therapy development relies on scientific innovation, delivery platform selection, supply chain resilience, and partnerships with healthcare institutions, with strategic distinction depending on aligning delivery technologies with pipeline priorities [4][9]. Industry Collaboration - Collaborative efforts between biotech firms and established pharmaceutical companies are accelerating clinical adoption and easing operational and regulatory integration, responding to heightened end-user demands for rapid production cycles and targeted therapies [9]. Market Insights - The report provides prioritized insights on RNA therapy pipelines and delivery technologies, aiding in adapting regulatory and supply chain strategies to shifting policies and supporting global operational flexibility [9].

Core Viewpoint - U.S. stock futures are lower, with significant declines in several companies' shares during pre-market trading, particularly Exelixis Inc, which reported preliminary financial results for fiscal year 2025 [1]. Group 1: Exelixis Inc - Exelixis reported preliminary US net product revenue of $2.123 billion for fiscal year 2025 [1]. - The company projects net product revenue for 2026 to be between $2.325 billion and $2.425 billion [1]. - Exelixis shares fell 4.6% to $42.01 in pre-market trading following the announcement [1]. Group 2: Other Companies - Synchrony Financial shares dipped 9.5% to $78.61 in pre-market trading [3]. - Stoke Therapeutics Inc declined 8.7% to $30.00, announcing updates on enrollment timelines and Phase 3 data for zorevunersen [3]. - Capital One Financial Corp fell 8.4% to $228.35 in pre-market trading [3]. - Bread Financial Holdings Inc tumbled 8.3% to $73.72 [3]. - Himalaya Shipping Ltd dipped 5.7% to $8.72 [3]. - Mesoblast Ltd fell 5.1% to $19.90, despite a previous gain after reporting increased sales [3]. - American Express Co declined 5% to $357.00 [3]. - Lumentum Holdings Inc fell 4.7% to $335.00 [3]. - WPP PLC declined 4.5% to $22.63 [3]. - Citigroup Inc fell 4% to $116.50, with earnings results expected on January 14 [3].

Core Viewpoint - Bark Inc's shares experienced a significant increase of 19.9% to $0.74 in pre-market trading following a non-binding acquisition proposal from Great Dane, as disclosed in a 13D filing [1] Gainers - Signing Day Sports Inc saw a substantial gain of 43.7% to $0.71 in pre-market trading [4] - Ping An Biomedical Co Ltd rose by 34.3% to $0.27 after a previous decline of 68% on Friday [4] - Abivax SA increased by 23.6% to $141.35, with Morgan Stanley analyst Judah Frommer maintaining an Overweight rating and raising the price target from $101 to $145 [4] - Cellectar Biosciences Inc gained 18.4% to $3.65 after a 7% drop on Friday [4] - China SXT Pharmaceuticals Inc surged 17.5% to $0.18 following an 88% decline on Friday, announcing a $10 million registered direct offering [4] - Kingsoft Cloud Holdings Ltd increased by 13.8% to $12.55 [4] - Critical Metals Corp rose 12.3% to $16.82 after an 11% increase on Friday [4] - Rich Sparkle Holdings Ltd gained 11.7% to $97.00, following a 259% jump on Friday after announcing a $39 million offering of 3 million shares at $13 per share [4] - 3 E Network Technology Group Ltd rose 10.3% to $0.41 after announcing the closing of a $2 million convertible promissory note offering [4] Losers - Lexaria Bioscience Corp fell 12.9% to $0.65 after a 7% gain on Friday [4] - Plus Therapeutics Inc declined 11.8% to $0.49, announcing an offering of 22,321,429 pre-funded units at $0.56 per unit [4] - RenovoRx Inc fell 11.3% to $0.99 after a 3% decline on Friday [4] - Synchrony Financial dipped 9.5% to $78.61 [4] - Eastern International Ltd shares decreased by 9.1% to $1.41 after a 30% increase on Friday [4] - Stoke Therapeutics Inc declined 8.7% to $30.00, announcing updates to timelines for the completion of enrollment and Phase 3 data readout from the EMPEROR study [4] - Capital One Financial Corp fell 8.4% to $228.35 [4] - Bread Financial Holdings Inc tumbled 8.3% to $73.72 [4] - OSR Holdings Inc decreased by 8% to $0.61 after a 6% gain on Friday [4] - Himalaya Shipping Ltd dipped 5.7% to $8.72 [4]

Core Insights - Oligonucleotide therapies are emerging as a significant breakthrough in the treatment of rare diseases, with over a dozen therapies approved globally and hundreds in clinical research, promising to benefit more patients in the future [1][14][15] Industry Developments - The global landscape has seen more than ten oligonucleotide therapies approved for rare diseases, providing new treatment options for conditions such as Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), and Hemophilia [1][14] - There are currently over a hundred oligonucleotide therapies in clinical development targeting various rare diseases, including siRNA and antisense oligonucleotide (ASO) therapies [2][14] Recent Approvals and Innovations - In August, Ionis Pharmaceuticals received FDA approval for the LICA drug Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older, marking it as the first RNA-targeted drug for HAE [4][18] - Ionis Pharmaceuticals and Sobi announced the approval of ASO drug Tryngolza (olezarsen) in the EU for treating genetically confirmed familial chylomicronemia syndrome (FCS) [4][19] - Alnylam Pharmaceuticals' siRNA therapy Amvuttra (vutrisiran) was approved by the FDA in March for treating patients with transthyretin amyloidosis with cardiomyopathy [5][19] Clinical Trial Progress - NS Pharma reported positive results from the long-term extension study of ASO therapy brogidirsen for DMD, showing effective exon 44 skipping and stable maintenance of motor function in patients [7][21] - RIBOMIC's umedaptanib pegol showed promising results in a Phase 2 trial for achondroplasia in children, with many patients experiencing improved height growth rates [7][21] - Ionis Pharmaceuticals' ASO therapy zilganersen demonstrated significant results in stabilizing walking speed in Alexander disease patients, with plans for a new drug application to the FDA in 2026 [8][22] WuXi TIDES Platform - WuXi TIDES has established an integrated solution for oligonucleotide and peptide therapies, covering custom synthesis, conjugation, process development, and CMC, facilitating the transition of innovative projects into clinical stages [1][11][26] - The platform offers comprehensive CRDMO services from drug discovery to commercial production, supporting high-throughput synthesis and custom synthesis for various oligonucleotides [11][26][27] Future Outlook - The company aims to continue leveraging its integrated CRDMO model to empower the development of various new drugs, including oligonucleotide therapies, to bring more effective treatments to patients [12][27]

Group 1: Market Movements - Biotech stocks experienced significant fluctuations in after-hours trading, with several companies rebounding after substantial losses during regular sessions, driven by fresh clinical data, FDA designations, and financing announcements [1] - Stoke Therapeutics, Inc. (STOK) saw its stock rise to $33.95 (+11.42%) in post-market hours after closing at $30.47 (-7.67%), following positive data presentations with Biogen regarding zorevunersen for Dravet syndrome [2] - Alpha Tau Medical Ltd. (DRTS) experienced a notable increase in share price, climbing to $5.30 (+25.26%) after closing at $4.23 (+8.74%), following the treatment of the first patient in its pilot study for recurrent glioblastoma multiforme [3] Group 2: Company Announcements - Absci Corp. (ABSI) rose to $3.65 (+3.69%) after hours, building on a close of $3.52 (+2.03%), with no new announcements but previously reported first volunteer dosing in its Phase 1/2a HEADLINE study of ABS-201 [4] - Senti Biosciences, Inc. (SNTI) surged to $1.60 (+3.92%) after hours, despite a sharp decline to $1.54 (-35.56%) during regular trading, driven by the FDA granting RMAT designation to its investigational CAR-NK cell therapy for AML and other hematologic malignancies [5] - TuHURA Biosciences, Inc. (HURA) edged up to $1.18 (+0.85%) after hours, following a significant decline to $1.17 (-40.91%) at the close, announcing a registered direct offering of 9.4 million shares priced at $1.65 per share [6]

Core Insights - Zorevunersen shows potential as a disease-modifying therapy for Dravet syndrome, demonstrating durable seizure reductions and improvements in cognition, behavior, and quality of life in patients [1][3][4] Clinical Data - Long-term Phase 1/2a and open label extension (OLE) studies indicate significant reductions in seizure frequency and increased seizure-free days for patients treated with zorevunersen alongside standard anti-seizure medicines [1][3][4] - A propensity score weighted analysis revealed that patients receiving zorevunersen experienced statistically significant reductions in major motor seizure frequency at six months, consistent with the ongoing Phase 3 EMPEROR study [5][6] - Improvements in cognition and behavior were observed at 18 months, with several assessments reaching statistical significance [5][6] Mechanism of Action - Analysis of electroencephalogram (EEG) data supports a disease-modifying mechanism of action for zorevunersen, showing dose-dependent effects in decreasing abnormal brain activity associated with Dravet syndrome [2][7] Safety Profile - Zorevunersen has been generally well tolerated, with 30% of patients in Phase 1/2a studies and 53% in OLE studies experiencing treatment-emergent adverse events (TEAEs) [8] - The most common TEAE was CSF protein elevations, occurring in 14% of patients in Phase 1/2a and 45% in OLE studies, with no related clinical manifestations observed [8] Future Directions - The ongoing Phase 3 EMPEROR study aims to further evaluate the efficacy and safety of zorevunersen in children with Dravet syndrome, with a focus on seizure frequency and improvements in behavior and cognition [12] - The collaboration between Biogen and Stoke Therapeutics is expected to advance the development and commercialization of zorevunersen for Dravet syndrome [11][16]

Core Insights - Zorevunersen shows potential as a disease-modifying therapy for Dravet syndrome, supported by four years of clinical data and EEG assessments [1][2][3] Company Overview - Biogen Inc. is a leading biotechnology company focused on innovative science to develop new medicines [7] - Stoke Therapeutics specializes in RNA medicine aimed at restoring protein expression, with zorevunersen as its first investigational product [9] Product Information - Zorevunersen is an investigational antisense oligonucleotide targeting the underlying cause of Dravet syndrome by increasing NaV1.1 protein production [5] - The drug has received orphan drug designation and Breakthrough Therapy Designation from the FDA for Dravet syndrome [5] Clinical Studies - The ongoing EMPEROR Phase 3 study evaluates zorevunersen's efficacy in children with Dravet syndrome, focusing on seizure frequency and cognitive improvements [6] - Data from the Phase 1/2a and ongoing open-label extension studies will be presented at the 2025 American Epilepsy Society Annual Meeting [2][3] Disease Context - Dravet syndrome is characterized by severe seizures and cognitive impairments, with a significant portion of patients not achieving adequate seizure control with existing treatments [4] - Approximately 38,000 individuals are estimated to be living with Dravet syndrome in the U.S., UK, EU-4, and Japan [4]

Group 1 - Biotech stocks are prominent on the IBD 50 list, with Stoke Therapeutics (STOK) and Mirum Pharmaceuticals (MIRM) either in or forming bases [1] - A specific biotech stock has shown a sell signal after a breakout that failed to progress [1] - Biotech companies have significantly rebounded from April lows, indicating a positive trend in the sector [1] Group 2 - Novo Nordisk's stock increased due to a lighter-than-expected discount for Ozempic and Wegovy under the Inflation Reduction Act, with a price cut of 71% for Ozempic [2]